FreeTheAI

Haemonetics Reaches 52-Week High on Q1 Revenue Growth and CSL Plasma Deal

BullishHigh impact
HAE$118.69 −0.65%

Haemonetics Corporation (NYSE:HAE) shares rallied about 17% to a 52-week high of $121 following the announcement of its first-quarter fiscal 2027 financial results and a major commercial agreement. The medical technology company reported revenue of $339 million, representing a 5.6% increase compared to the previous period, while earnings per share rose to $0.72 from $0.70 despite a 3% drop in net income.

Alongside the quarterly earnings report, Haemonetics secured a supply agreement with CSL Plasma. Under the deal, CSL Plasma will transition its U.S. collection centers to Haemonetics' NexSys PCS platform, utilizing its devices and disposable supplies.

Investors will be monitoring the implementation of the CSL Plasma transition through 2027, as well as how future quarterly reports balance revenue expansion against net income performance.

Key points

  • Haemonetics Corporation (NYSE:HAE) reported Q1 fiscal 2027 revenue of $339 million, up 5.6%.
  • Earnings per share increased to $0.72 from $0.70, while net income declined 3%.
  • Haemonetics signed a supply deal for CSL Plasma to adopt its NexSys PCS platform through 2027.
  • The company's stock jumped roughly 17% to reach a 52-week high of $121.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

Why did Haemonetics stock reach a 52-week high?

Haemonetics stock rose after reporting a 5.6% increase in Q1 fiscal 2027 revenue to $339 million and securing a U.S. supply agreement with CSL Plasma.

What was Haemonetics' Q1 fiscal 2027 revenue and EPS?

Haemonetics reported revenue of $339 million and earnings per share of $0.72 for Q1 fiscal 2027, compared to $0.70 per share in the prior period.

What is the CSL Plasma agreement with Haemonetics?

CSL Plasma agreed to transition its U.S. centers to Haemonetics' NexSys PCS platform, using its devices and disposable products through 2027.